143572-60-5

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 4-(bromomethyl)-2-chloro-, methyl ester is used as an intermediate in the synthesis of pharmaceuticals for its ability to be chemically modified and incorporated into various drug molecules.
Used in Agrochemical Industry:
Benzoic acid, 4-(bromomethyl)-2-chloro-, methyl ester is used as an intermediate in the synthesis of agrochemicals for its potential to be utilized in the development of pesticides and other agricultural products.
Used in Chemical Production:
Benzoic acid, 4-(bromomethyl)-2-chloro-, methyl ester is used as a raw material in the production of various chemicals such as dyes, perfumes, and plasticizers due to its versatile chemical structure and reactivity.
Used in Research and Development:
Benzoic acid, 4-(bromomethyl)-2-chloro-, methyl ester has potential applications in the field of medicine and other industrial processes, making it a valuable compound for research and development purposes.

Upstream product

• 7697-25-8 2-chloro-4-methylbenzoic acid 
• 195318-63-9 methyl 2-chloro-4-methylbenzoate 
• 138642-63-4 2-chloro-4-methylphenyl trifluoromethanesulfonate 
• 6640-27-3 2-chloro-p-cresol 

Downstream Products

• 916913-65-0 methyl 2-chloro-4-{[2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-5-(trifluoromethyl)phenoxy]methyl}benzoate 

Relevant academic research and scientific papers

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.

Mild Benzylic Monobromination of Methyl Toluates in Aqueous CTAB

A strategy has been developed for the regioselective monobromination of methyl toluates by using tert-butylhydrogen peroxide and potassium bromide (TBHP/KBr) in a cetyltrimethylammonium bromide (CTAB) micellar medium. Ultrasonic and microwave-assisted protocols recorded increased rates and product yields under mild reaction conditions, coupled with a straightforward isolation procedure.

IMIDAZOLE CARBOXAMIDES

The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.

Optimization of sulfonamide derivatives as highly selective EP1 receptor antagonists

A series of 4-[(2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}phenoxy)methyl]benzoic acids and 4-({2-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]phenoxy}methyl)benzoic acids were synthesized and evaluated for their EP receptor affinities and EP1 receptor anta